 
                                  Pablo Corral/LinkedIn
                         
                                                                  Oct 29, 2025, 07:39 
                                
                                Pablo Corral: Pushing the Limits of LDLc: Emerging Paradigms in CV Risk Reduction
Pablo Corral, Past President of Argentine Lipid Society, has shared a post on LinkedIn:
“Pushing the limits of LDLc: Emerging paradigms in CV risk reduction
- Modern guidelines now target LDL-C <55 mg/dL, and even <40 mg/dL for the highest-risk patients.
- Evidence from FOURIER, ODYSSEY, and IMPROVE-IT confirms that the lower, the better — with no safety concerns, even below 25 mg/dL.
- Genetic data (PCSK9 LoF, APOB, ANGPTL3) reinforce that lifelong low LDL-C protects against ASCVD.
- Emerging therapies — PCSK9 inhibitors, inclisiran, bempedoic acid, ANGPTL3 inhibitors — make these targets achievable.
- Cognitive, endocrine, and hemorrhagic risks remain none at very low LDL-C.
The real challenge is no longer how low can we go, but how many actually get there.”

Stay updated with Hemostasis Today.
- 
                    Oct 31, 2025, 14:17When Stories Save Lives: Reza Shojaei Shares Blood and Plasma Pulse Newest Issue
- 
                    Oct 31, 2025, 13:34Charlotte Pilling Invites You to ''Women in Hematology'' US Focus Meeting
- 
                    Oct 30, 2025, 12:12Laura Ceci Galanos Reflects on WSC 2025
- 
                    Oct 30, 2025, 07:56Vallabh Janardhan: Strokes Affecting Younger Patients
- 
                    Oct 30, 2025, 07:55“Marrow Asleep or Awake?”: William Aird Simplifies Anemia Diagnosis
- 
                    Oct 31, 2025, 13:47Bethany Brown and Colleagues Present Recommendations on DEHP Alternatives
- 
                    Oct 30, 2025, 07:52Haemophilia B - An illustrative review of current challenges and opportunities
- 
                    Oct 30, 2025, 05:14Umberto Pensato on Reperfusion Outcomes in Stroke
- 
                    Oct 29, 2025, 07:39Pablo Corral: Pushing the Limits of LDLc: Emerging Paradigms in CV Risk Reduction
- 
                    Oct 29, 2025, 07:38Thijs van Haaps and Team Show That Andexanet Alfa May Go Beyond Apixaban and Rivaroxaban
- 
                    Oct 29, 2025, 07:31The Use of Artificial Intelligence to Improve Detection of Acute Incidental Pulmonary Emboli - JTH
- 
                    Oct 29, 2025, 07:05Shrinidhi Nathany: AI in Diagnostic Medicine
- 
                    Oct 28, 2025, 07:02Aya Berman: AI Model for Predicting Bacteremia
- 
                    Oct 28, 2025, 06:55The New Era of Genomics, AI and Cell Therapy in Hematology and Infectious Diseases
- 
                    Oct 28, 2025, 06:49Lukas Gaats: Researchers Are Building Reproductive Organoids
- 
                    Oct 31, 2025, 14:41Emilya Huseynova Reflects on AABB 2025
- 
                    Oct 31, 2025, 14:33Cihan Ay Delivers Seminar at McMaster University on Thrombosis Research
- 
                    Oct 31, 2025, 14:25Thomas Reiser Steps Down as ISTH Executive Director After 14+ Years of Leadership
- 
                    Oct 31, 2025, 14:02Murray Adams Reflects on His Week Attending Blood 2025
- 
                    Oct 31, 2025, 13:10Angelique Balguid: World Stroke Day is More Than a Moment — It’s a Movement
Oct 31, 2025, 14:41 
                        
                    Oct 31, 2025, 14:33 
                        
                    Oct 31, 2025, 14:02 
                        
                    Oct 31, 2025, 13:47 
                        
                    Oct 31, 2025, 13:34 
                        
                    Oct 31, 2025, 13:10 
                        
                    Oct 30, 2025, 12:12 
                        
                    